US OptionsDetailed Quotes
CRDL240719C7500
- 0.09
- 0.000.00%
15min DelayClose Jul 19 12:56 ET
0.00High0.00Low
0.09Open0.09Pre Close0 Volume13 Open Interest7.50Strike Price0.00Turnover8521.96%IV263.16%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier0DDays to Expiry0.09Extrinsic Value100Contract SizeAmericanOptions Type0.1386Delta0.1250Gamma23.22Leverage Ratio-5.2675Theta0.0000Rho3.22Eff Leverage0.0000Vega
Cardiol Therapeutics Stock Discussion
Sign in to post a comment
$Cardiol Therapeutics(CRDL.US$
Cardiol Therapeutics Announces Positive Topline Data from its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis
Cardiol Therapeutics announced positive topline data from its Phase II MAvERIC-Pilot study, evaluating CardiolRxTM for treating recurrent pericarditis. The 8-week clinical data showed a significant reduction in pericarditis pain and inflammation. The study involved 27 patients, and 89% continued into the extension ph...
Cardiol Therapeutics Announces Positive Topline Data from its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis
Cardiol Therapeutics announced positive topline data from its Phase II MAvERIC-Pilot study, evaluating CardiolRxTM for treating recurrent pericarditis. The 8-week clinical data showed a significant reduction in pericarditis pain and inflammation. The study involved 27 patients, and 89% continued into the extension ph...
1
5
4
$Cardiol Therapeutics(CRDL.US$
NEWS
Cardiol Therapeutics Announces Phase II ARCHER Trial Presented at the World Congress on Acute Heart Failure 2024
Cardiol Therapeutics presented its Phase II ARCHER trial at the World Congress on Acute Heart Failure 2024. The trial is evaluating CardiolRx™ in patients with acute myocarditis. The presentation included the trial design, rationale, and baseline data on the first 50 patients randomized. The ARCHER trial has exceeded 85% of target enrollment, with ...
NEWS
Cardiol Therapeutics Announces Phase II ARCHER Trial Presented at the World Congress on Acute Heart Failure 2024
Cardiol Therapeutics presented its Phase II ARCHER trial at the World Congress on Acute Heart Failure 2024. The trial is evaluating CardiolRx™ in patients with acute myocarditis. The presentation included the trial design, rationale, and baseline data on the first 50 patients randomized. The ARCHER trial has exceeded 85% of target enrollment, with ...
1
1
$Cardiol Therapeutics(CRDL.US$ Cardiol is well positioned to achieve significant milestones in the MAvERIC, ARCHER, and CRD-38 programs during 2024. There is supposedly a data release coming before end of 1H! NFA just thinking outloud!![]()
2
2
$Cardiol Therapeutics(CRDL.US$ Cardiol Therapeutics Completes Patient Enrollment in Its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis![]()
1
9
$Cardiol Therapeutics(CRDL.US$ Its trying to get back to the HOD that happened earlier when i posted the FDA approval PR![]()
1
$Cardiol Therapeutics(CRDL.US$Moomoo 24/7· 2 mins ago
Cardiol Therapeutics Says FDA Granted Orphan Drug Designation For Its Lead Drug Candidate For Treatment Of Pericarditis![]()
Cardiol Therapeutics Says FDA Granted Orphan Drug Designation For Its Lead Drug Candidate For Treatment Of Pericarditis
$Cardiol Therapeutics(CRDL.US$ Cardiol Therapeutics Regains Compliance With All Applicable Listing Standards of The Nasdaq Capital Market![]()
$Cardiol Therapeutics(CRDL.US$ Cardiol Therapeutics Exceeds 50% Enrollment In Phase II ARCHER Trial In Acute Myocarditis![]()
No comment yet
Anil Datta : Price dropped and 10 time stocks traded any guess what happened?
Jaguar8OP Anil Datta: Always expect shorts to attack
Anil Datta Jaguar8OP: When shorts attack price normally goes down?
Jaguar8OP Anil Datta: Definitely.
Anil Datta Jaguar8OP: Good morning any other stocks you are fallowing Can you share please